The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 42 | — | 20.1x | Near average | |
Growth | 86 | 50.7% | 5.6% | Above average | |
Quality | 43 | -0.2% | 7.6% | Near average | |
Safety | 26 | 4.8x | 0.4x | Below average | |
Capital Return | 5 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Alvotech is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Alvotech shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Alvotech stock has experienced a notable decline in analyst optimism, with the average price target dropping by 33.3% to reach $5, down from $7.5. The current consensus shows a complete alignment among the three analysts (High/Low/Median at $5), indicating a collective and organized downward reassessment of the stock's fair value, coinciding with major rating downgrades from institutions such as Barclays and Deutsche Bank.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.